medigraphic.com

2019, Number 2

<< Back Next >>

Enf Infec Microbiol 2019; 39 (2)

Human immunodeficiency virus: useful findings in diagnosis, prevention and treatment

Carvajal AM, Roldán TMD, Herrera AL, Hernández MA, Álvarez HLF, Martínez SLM

Language: Spanish
References: 53
Page: 65-70
PDF size: 231.63 Kb.


ABSTRACT

HIV infection is a worldwide problem and its prevalence continues to rise, nonetheless, thanks to the advances in antiretroviral therapy, mortality has diminished considerably. Between 2000 and 2016, new HIV infections lowered in 39% and HIV-related deaths lowered in 33% with 13.1 million lives, saving in antiretroviral therapy in a similar period. HIV-1 entry into CD4 cells implies glycoprotein interactions such as the envelope’s gp120 and a secondary coreceptor, either one of two chemokines receptors CCR5 or CXCR4; the presence of a mutation in one of those gives a new direction on infection’s treatment and provides an effective alternative to long-term HIV/AIDS treatment medications. For diagnosis, rapid tests represent an accessible and swift method, but must be accompanied by protocols that allow complimentary exams for diagnosis confirmation. Prophylaxis has shown to be effective in prevention of HIV acquisition in at-risk populations, such as health-care professionals that suffer from needle lesions and in vertical transmission from hiv positive mothers to their newborns; also, it has been shown that its application reduces HIV conversion rates among people with consensual sexual expositions.


REFERENCES

  1. Reitz, S.M. y Gallo, R.C., “Virus de la inmunodeficiencia humana”, en Mandell, Enfermedades infecciosas. Principios y prácticas, 8ª ed., Elsevier, Madrid, 2016, pp. 2163-2175.

  2. Shah, H.R. y Savjani, J.K., “Recent updates for designing ccr5 antagonists as anti-retroviral agents”, Eur J Med Chem, 2018, 147: 115-129.

  3. Instituto Nacional de Salud, Colombia: Cuéllar N, marzo de 2019, Informe de evento vih/sida, Colombia, 2017, disponible en: https://www.ins.gov.co/buscador-eventos/ Informesdeevento/VIH-SIDA%202017.pdf.

  4. Panel of experts from the National aids Plan (pns), aids Study Group (Gesida), Spanish Society of Occupational Health Safety at Work (semst), Spanish Society of Preventive Medicine Public Health Hygiene (sempsph), Spanish Association of Specialists in Occupational Medicine (aeemt), Spanish Society of Occupational Health in Public Administration (seslap) et al., “Executive summary of the consensus document on post-exposure prophylaxis against hiv, hbv and hcv in adults and children”, Enferm Infecc Microbiol Clin, 2016, 34 (2): 122-131.

  5. Hurt, C.B., Nelson, J.A.E., Hightow-Weidman, L.B. y Miller, W.C., “Selecting an hiv test: a narrative review for clinicians and researchers”, Sex Transm Dis, 2017, 44 (12): 739-746.

  6. Shrestha, R., Philip, S., Shewade, H.D., Rawal, B. Deuba, K., “Why don’t key populations access hiv testing and counselling centres in Nepal? Findings based on national surveillance survey”, bmj Open, 2017, 7 (12): e017408.

  7. Cardona-Duque, D.V., Medina-Pérez, O.A., Herrera, S.M. y Orozco, P.A., “Depresión y factores asociados en personas viviendo con vih/sida en Quindío, Colombia, 2015, Revista Habanera de Ciencias Médicas, 2016, 15 (6): 941-954.

  8. Ismail, S., Awan, S., Naeem, R., Siddiqui, S., Afzal, B., Jamil, B. et al., “Occupational exposure to hiv in a developing country: assessing knowledge and attitude of healthcare professional before and after an awareness symposium”, bmc Res Notes, 2018, 11 (1): 131.

  9. Crutcher, J.M., Lamm, S.H. y Hall, T.A., “aids series: paper iii-b. Prevention of hiv transmission in the workplace: categorization of jobs and tasks by risk of hiv infection”, Am Ind Hyg Assoc J, 1991, 52 (1): A14-6.

  10. Domkam, I.K., Sonela, N., Kamgaing, N., Takam, P.S., Gwom, L.C., Betilene, T.M.A. et al., “Prevalence and risk factors to hiv-infection amongst health care workers within public and private health facilities in Cameroon”, Pan Afr Med J, 2018, 29: 158.

  11. Mabwe, P., Kessy, A.T. y Semali, I., “Understanding the magnitude of occupational exposure to human immunodeficiency virus (hiv) and uptake of hiv post-exposure prophylaxis among healthcare workers in a rural district in Tanzania”, J Hosp Infect, 2017, 96 (3): 276-280.

  12. Mandić, B., Mandić-Rajčević, S., Marković-Denić, L. y Bulat, P., “Occupational exposure to blood and bodily fluids among healthcare workers in Serbian general hospitals”, Arh Hig Rada Toksikol, 2018, 69 (1): 61-68.

  13. Gańczak, M. y Szych, Z., “hbv, hcv, and hiv infection prevalence among prison staff in the light of occupational risk factors”, Med Pr, 2017, 68 (4): 507-516.

  14. Cashin, K., Jakobsen, M.R., Sterjovski, J., Roche, M., Ellett, A,. Flynn, J.K. et al., “Linkages between hiv-1 specificity for ccr5 or cxcr4 and in vitro usage of alternative coreceptors during progressive hiv-1 subtype c infection”, Retrovirology, 2013, 10: 98.

  15. Hikichi, Y., Yokoyama, M., Takemura, T., Fujino, M., Kumakura, S., Maeda, Y. et al., “Increased hiv-1 sensitivity to neutralizing antibodies by mutations in the Env v3-coding region for resistance to cxcr4 antagonists”, J Gen Virol, 2016, 97 (9): 2427-2440.

  16. Hongjaisee, S., Braibant, M., Barin, F., Ngo-Giang-Huong, N., Sirirungsi, W. y Samleerat, T., “Effect of amino acid substitutions within the v3 Region of hiv-1 crf01_ae on interaction with ccr5-coreceptor”, aids Res Hum Retroviruses, 2017, 33 (9): 946-951.

  17. Badia, R., Riveira-Muñoz, E., Clotet, B., Esté, J.A. y Ballana, E., “Gene editing using a zinc-finger nuclease mimicking the ccr5Δ32 mutation induces resistance to ccr5-using hiv-1”, J Antimicrob Chemother, 2014, 69 (7): 1755-1759.

  18. Allers, K., Hütter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E. et al., “Evidence for the cure of hiv infection by ccr5Δ32/Δ32 stem cell transplantation”, Blood, 2011, 117 (10): 2791-2799.

  19. Shi, B., Li, J., Shi, X., Jia, W., Wen, Y., Hu, X. et al., “talenmediated knockout of ccr5 confers protection against infection of human immunodeficiency virus”, J Acquir Immune Defic Syndr, 2017, 74 (2): 229-241.

  20. Espy, N., Pacheco, B. y Sodroski, J., “Adaptation of hiv- 1 to cells with low expression of the ccr5 coreceptor”, Virology, 2017, 508: 90-107.

  21. Garg, H., Lee, R.T., Maurer-Stroh, S. y Joshi, A., “hiv-1 adaptation to low levels of ccr5 results in v3 and v2 loop changes that increase envelope pathogenicity, ccr5 affinity and decrease susceptibility to maraviroc”, Virology, 2016, 493: 86-99.

  22. Kou, J. y Kuang, Y.Q., “Mutations in chemokine receptors and aids”, Prog Mol Biol Transl Sci, 2019, 161: 113-124.

  23. Stekler, J.D., Violette, L.R., Niemann, L., McMahan, V.M., Katz, D.A., Beaten, J.M. et al., “Repeated false-positive hiv test results in a patient taking hiv pre-exposure prophylaxis”, Open Forum Infect Dis, 2018, 5 (9): ofy197.

  24. Ndase, P., Celum, C., Kidoguchi, L., Ronald, A., Fife, K.H., Bukusi, E. et al., “Frequency of false positive rapid hiv serologic tests in African men and women receiving prep for hiv prevention: implications for programmatic roll-out of biomedical interventions”, plos One, 2015, 10 (4): e0123005.

  25. Olaru, I.D., McHugh, G., Dakshina, S., Majonga, E., Dauya, E., Bandason, T. et al., “False-negative hiv tests using oral fluid tests in children taking antiretroviral therapy from Harare, Zimbabwe”, J Int aids Soc, 2017, 20 (Suppl 6): 21751.

  26. Merchant, M., Wright, M., Kabat, W. y Yogev, R., “Longterm highly suppressed hiv-infected children and adolescents with negative rapid hiv tests due to significant antibody loss”, J Clin Virol, 2014, 59 (3): 172-176.

  27. Simoncini, G.M., Megill, M. y Van den Berg-Wolf, M., “Reducing false-positive hiv diagnosis in Niger: a women’s issue”, J Int Assoc Provid aids Care, 2016, 15 (1): 15-18.

  28. Kosack, C.S., Page, A.L., Beelaert, G., Benson, T., Savane, A., Ng’ang’a A. et al., “Towards more accurate hiv testing in sub-Saharan Africa: a multi-site evaluation of hiv rdts and risk factors for false positives”, J Int aids Soc, 2017, 19 (1): 21345.

  29. Curlin, M.E., Gvetadze, R., Leelawiwat, W., Martin, M., Rose, C., Niska, R.W. et al., “Analysis of false-negative human immunodeficiency virus rapid tests performed on oral fluid in 3 international clinical research studies”, Clin Infect Dis, 2017, 64 (12): 1663-1669.

  30. Shanks, L., Ritmeijer, K., Piriou, E., Siddiqui, M.R., Kliescikova, J., Pearce, N. et al., “Accounting for false positive hiv tests: is visceral leishmaniasis responsible?”, plos One, 2015, 10 (7): e0132422.

  31. Muthukumar, A., Alatoom, A., Burns, S., Ashmore, J., Kim, A., Emerson, B. et al., “Comparison of 4th-generation hiv antigen/ antibody combination assay with 3rd-generation hiv antibody assays for the occurrence of false-positive and false-negative results”, Lab Med, 2015, 46 (2): 84-89, quiz e28-9.

  32. Adhikari, E.H., Macias, D., Gaffney, D., White, S., Rogers, V.L., McIntire, D.D. et al., “Diagnostic accuracy of fourth-generation Architect hiv Ag/Ab Combo assay and utility of signal-tocutoff ratio to predict false-positive hiv tests in pregnancy”, Am J Obstet Gynecol, 2018, 219 (4): 408.e1-408.e9.

  33. Akl, P. y Blick, K.E., “A case of false-positive test results in a pregnant woman of unknown hiv status at delivery”, Lab Med, 2014, 45 (3): 259-263.

  34. Wang, L., Xiao, Y., Tian, X.D., Ruan, J.X., Chen, W. y Yu, Y., “hiv infection in Xi’an, China: epidemic characterization, risk factors to false positives and potential utility of the sample-to-cutoff index to identify true positives using Architect hiv Ag/Ab combo”, Antimicrob Resist Infect Control, 2019, 8: 9.

  35. Hardie, D.R., Korsman, S.N., Hsiao, N.Y., Morobadi, M.D., Vawda, S. Goedhals, D., “Contamination with hiv antibody may be responsible for false positive results in specimens tested on automated platforms running hiv 4th generation assays in a region of high hiv prevalence”, plos One, 2017, 12 (7): e0182167.

  36. Lavoie, S., Caswell, D., Gill, M.J., Kadkhoda, K., Charlton, C.L., Levett, P.N. et al., “Heterophilic interference in specimens yielding false-reactive results on the abbott 4th generation Architect hiv Ag/Ab Combo assay”, J Clin Virol, 2018, 104: 23-28.

  37. Smotrys, M., Magge, T., Alkhuja, S. y Gandotra, S.D., “Babesiosis as a cause of false-positive hiv serology”, bmj Case Rep, 2018, pii: bcr-2017-223738.

  38. Jian, L., Liang, W., Zhang, Y., Li, L., Mei, Y., Tan, R. et al., “Systemic lupus erythematosus patient with false positive results of antibody to hiv: a case report and a comprehensive literature review”, Technol Health Care, 2015, 23 Suppl 1: S99-S103.

  39. Li, Y.C., Yang, F., Ji, X.Y., Fang, Z.J., Liu, J. y Wang, Y., “False human immunodeficiency virus test results associated with rheumatoid factors in rheumatoid arthritis”, Chin Med Sci J, 2014, 29 (2): 103-106.

  40. Liu, M.Q., Zhu, Z.R., Kong, W.H., Tang, L., Peng, J.S., Wang, X. et al., “High rate of missed hiv infections in individuals with indeterminate or negative hiv western blots based on current hiv testing algorithm in China”, J Med Virol, 2016, 88 (8): 1462-1466.

  41. Ariza-Heredia, E.J., Granwehr, B.P., Viola, G.M., Bhatti, M., Kelley, J.M., Kochenderfer, J. et al., “False-positive hiv nucleic acid amplification testing during car t-cell therapy”, Diagn Microbiol Infect Dis, 2017, 88 (4): 305-307.

  42. Laetsch, T.W., Maude, S.L., Milone, M.C., Davis, K.L., Krueger, J., Cárdenas, A.M. et al., “False-positive results with select hiv-1 nat methods following lentivirus-based tisagenlecleucel therapy”, Blood, 2018, 131 (23): 2596- 2598, doi: 10.1182/blood-2017-12-822940.

  43. Álvarez, P., Martín, L., Prieto, L., Obiang, J., Vargas, A., Avedillo, P. et al., “hiv-1 variability and viral load technique could lead to false positive hiv-1 detection and to erroneous viral quantification in infected specimens”, J Infect, 2015, 71 (3): 368-376.

  44. Oladokun, R., Korsman, S., Ndabambi, N., Hsiao, N., Hans, L., Williamson, C. et al., “False-negative hiv-1 polymerase chain reaction in a 15-month-old boy with hiv-1 subtype c infection”, S Afr Med J, 2015, 105 (10): 877.

  45. Desai, M., Field, N., Grant, R. y McCormack, S., “Recent advances in pre-exposure prophylaxis for hiv”, bmj, 2017, 359: j5011.

  46. Sánchez, J., Martínez, J.M., Navarro, H., Fernández, S., Escobar, I. y Ventura, J.M., “Perceptions about hiv preexposure prophylaxis among healthcare professionals in Spain (perppres Study)”, Farm Hosp, 2016, 40 (4): 287-301.

  47. Buchbinder, S.P., Glidden, D.V., Liu, A.Y., McMahan, V., Guanira, J.V., Mayer, K.H. et al., “hiv pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial”, Lancet Infect Dis, 2014, 14 (6): 468-475.

  48. Aguirre, A.O., Vera, M., Puerta, T., Raposo, M., Rodríguez, C. y Del Romero, J., “To whom is hiv pre-exposure prophylaxis proposed?”, Enferm Infecc Microbiol Clin, 2017, 35 (5): 299-302.

  49. Gallagher, T., Link, L., Ramos, M., Bottger, E., Aberg, J. y Daskalakis, D., “Self-perception of hiv risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for hiv at commercial sex venues in New York City”, lgbt Health, 2014, 1 (3): 218-224.

  50. Antela, A., Azcoaga, A., Sampedro, E. y Poveda, T., “Primary prevention”, Enferm Infecc Microbiol Clin, 2018, 36 Suppl 1: 31-34.

  51. Cresswell, F., Waters, L., Briggs, E., Fox, J., Harbottle, J., Hawkins, D. et al., “UK guideline for the use of hiv postexposure prophylaxis following sexual exposure, 2015”, Int J std aids, 2016, 27 (9): 713-738.

  52. Scannell, M., MacDonald, A.E., Berger, A. y Boyer, N., “The priority of administering hiv postexposure prophylaxis in cases of sexual assault in an emergency department”, J Emerg Nurs, 2018, 44 (2): 117-122.e1.

  53. Ajayi, A.I., Ismail, K.O., Adeniyi, O.V. y Akpan, W., “Awareness and use of pre exposure and postexposure prophylaxes among Nigerian university students: findings from a cross-sectional survey”, Medicine (Baltimore), 2018, 97 (36): e12226.




2020     |     www.medigraphic.com